You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. AstraZeneca's Imfinzi gets EU recommendation, Serica Energy extends Rhum licence
- 2. CHMP recommends subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
- 3. Study finds key biomarker to predict KRASG12C inhibitor effectiveness in lung cancer
- 4. CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- 5. Police officers over 40 offered free lung cancer screening
- 6. BriaCell immunotherapy destroys metastatic breast cancer tumor
- 7. Lung cancer is increasing in non-smokers - this might be why
- 8. The role of lactylation in tumor growth and cancer progression
- 9. Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis
- 10. Long term survival of advanced hepatoid adenocarcinoma of lung secondary to idiopathic pulmonary fibrosis: a case report
Last updated at 4:46 GMT
Hot News Makers
Health/Pharma Companies
-
60351.04
-
41177.23
-
16984.29
-
10162.88
-
7275.92
-
6713.69
-
6115.01
-
5885.67
-
5632.00
-
5005.57
Drugs, Treatments, Trials
-
101093.92
-
58213.53
-
42539.30
-
10610.31
-
6428.02
-
5599.98
-
4628.50
-
4210.18
-
3710.47
-
3360.18
Last updated at 4:10 GMT
